MedTrace Logo

Drug Test Detection of Cocaine for Nasal Intubation

NCT05334056 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2023-06-01

No results posted yet for this study

Summary

The objective of this study is to determine whether it is possible to detect traces above national cut-offs of either cocaine's main metabolite benzoylecgonine in saliva or cocaine in blood 24 hours after administering 2 ml of 40 mg/ml cocaine-saline to the nasal mucosa.

The investigators hypothesize that the level of cocaine's main metabolite bezoylecgonine in saliva after cocaine administered for anesthetic purposes will be below detection limits after 24 hours.

Conditions

  • Cocaine Adverse Reaction

Interventions

DRUG

Cocaine Nasal

2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Mo Haslund Larsen, MD · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-22
Primary Completion
2023-05-27
Completion
2023-05-27

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05334056 on ClinicalTrials.gov